1. Introduction
===============

Pilocytic astrocytoma (PA) is a common World Health Organization (WHO) grade I glioma occurring in children and adolescents. Most PAs show benign clinical behavior and favorable prognosis. But in a small subset of patients, they may behave aggressively.^\[[@R1],[@R2]\]^ Under the microscopy, besides classical biphasic architecture, morphological heterogeneity may be found in PAs, which simulates the characteristics of the other low-grade glial neoplasms, such as oligdendroglioma, pleomorphic xanthoastrocytoma (PXA), ependymoma, and diffuse astrocytoma.^\[[@R3]\]^ However, PAs that are histopathologically similar to dysembryoplastic neuroepithelial tumors (DNTs) in both histological morphology and immunophenotype have not been reported before. We herein showed a DNT-like PA case, which expanded the morphological profile of PA.

2. Case report
==============

A 22-year-old male visited local hospital due to a car accident in November 2016. CT scans detected a mass located in the right temporal-occipital lobe. The patient refused to do any treatment because of no clinical symptoms at that time. Two months later, he presented with a focal epilepsy, which was improved after having anti-epileptic drugs. In February 2017, he was referred to our hospital (Southern District of Anhui Provincial Hospital) because of deteriorating symptom. Magnetic resonance imaging (MRI) examination revealed a 1.1 × 1 × 1 cm round homogenous mass, which was hyperintense on T2 (Fig. [1](#F1){ref-type="fig"}A) and slightly hypointense on T1 weighted images (Fig. [1](#F1){ref-type="fig"}B) without gadolinium enhancement (Fig. [1](#F1){ref-type="fig"}C). The patient denied having any family history of neurofibromatosis type 1 (NF1) and no associated symptoms were found during the previous physical examinations. The lesion was totally removed via a right temporal-occipital craniotomy. Intraoperatively, the lesion was well circumscribed without obvious capsule. The substance within the tumor was jelly like.

![Neuroradiologic features of DNT-like PA. (A) Axial T2-weighted MRI showed a 1.1 × 1 × 1 cm round homogenous hyperintense mass in right temporal-occipital lobe. (B) Axial T1-weighted MRI showed slightly hypointense mass. (C) Contrast-enhanced T1-weighted MRI showed no enhancement of the mass. DNT = dysembryoplastic neuroepithelial tumor, PA = pilocytic astrocytoma.](medi-97-e10755-g001){#F1}

The resected tissue was fixed in 10% neutral buffered formalin for pathological study. Histomorphologically, a distinctive microcystic pattern was detected (Fig. [2](#F2){ref-type="fig"}A). The tumor cells had uniform round to oval nuclei without any observed mitoses. A small amount of hyperchromatic nuclei were scattered distribution within microcystic background. The classical biphasic pattern with a mixture of loose microcystic and compact regions of PAs were not examined. Immunohistochemistry assay revealed that the tumor cells were diffusely positive for GFAP (Fig. [2](#F2){ref-type="fig"}B) and Olig2 (Fig. [2](#F2){ref-type="fig"}C). In contrast, IDH1 (Fig. [2](#F2){ref-type="fig"}D), BRAF V600E, H3K27M, CD34 and p53 staining cells were not detected in the tumor. The Ki67 labeling index was \<1% (Fig. [2](#F2){ref-type="fig"}E). Confusingly, neuronal marker NeuN was expressed in tumor cells scattered in the background which normally found in DNT (Fig. [2](#F2){ref-type="fig"}F). To confirm the diagnosis, further assay with fluorescence in situ hybridization (FISH) was applied and *KIAA1549--BRAF* fusion gene was found in the tumor (Fig. [3](#F3){ref-type="fig"}). The final diagnosis was DNT-like PA (WHO grade I).

![Pathological findings of DNT-like PA. (A) Hematoxylin-eosin section of DNT-like PA showed a distinctive microcystic pattern. Immunochemistry staining revealed diffuse expression of GFAP (B) and Olig2 (C). (D) The tumor cells were negative for IDH1. (E) The Ki67 labeling index was less than 1%. (F) Neuronal marker NeuN was expressed in tumor cells scattered in the background. The image magnification of (A--D, F) is ×200, € is ×400. DNT = dysembryoplastic neuroepithelial tumor, GFAP = glial fibrillary acidic protein, IDH1 = isocitrate dehydrogenase 1, PA = pilocytic astrocytoma.](medi-97-e10755-g002){#F2}

![The *KIAA1549--BRAF* fusion gene was positive by fluorescence in situ hybridization (FISH) analysis. FISH = fluorescence in situ hybridization.](medi-97-e10755-g003){#F3}

Ethical approval was not required for this case report as it did not relate to any human trials or the patient\'s privacies. Informed consent was provided by the patient for the publication of this case report.

3. Discussion
=============

PA is a clinicopathological heterogeneous WHO grade I tumor.^\[[@R3],[@R4]\]^ Clinically, PAs accounts for 20% of brain tumors in the patients under 20 years old.^\[[@R5]\]^ Approximately 5% to 10% PAs are associated with neurofibromatosis type 1 (NF1), especially those cases which arise in the optic/chiasmatic region.^\[[@R6]\]^ PAs mainly involve the neuraxis, such as cerebellum, optic pathway, hypothalamus, brainstem, and spinal cord, while the supratentorial region is also frequently encountered.^\[[@R3],[@R6]\]^ Clinical manifestations of PAs are dependent on the lesion locations. Neuroradiologically, PAs typically show hypo- or iso-intense lesion on T1-weighted images with enhancement and hyperintense on T2-weighted images. Most lesions in the cerebellum are cystic accompanying with a mural enhancing nodule under MRI, while others display as infiltrative masses in the optic pathway.^\[[@R7]\]^ However, just like our case, the imaging findings of the lesions can be atypical in other areas.^\[[@R7]\]^ Instead of typical contrast enhancement under MRI, they showed an atypical solid mass without cystic change and infiltration.

Histologically, PAs typically show biphasic pattern with a mixture of loose microcystic and compact regions. In the loose microcystic parts, esoinopholic granular bodies can be seen. Meanwhile, the bipolar piloid cells compose the compact areas, in which rosenthal fibres are easily detected. Occasionally, PAs exhibited a predominantly or even entirely growth pattern.^\[[@R3]\]^ It is not unusual to find heterogeneous morphological characteristics in PAs, such as oligdendroglioma, PXA, ependymoma, and diffuse astrocytoma.^\[[@R3]\]^ However, PA with NeuN positive cells in entirely microcystic background which mimicked DNT was not reported in the literature before. The exact reason for this is not clear. We inferred that these NeuN positive cells may be entrapped neurons or due to unspecific immunohistochemical reactions.

In addition to clinicopathological heterogeneity, PAs also display molecular heterogeneity. Jones et al^\[[@R8]\]^ firstly found the *KIAA1549--BRAF* fusion gene exhibited in most of the PAs. This fusion gene can activate the mitogen-activated protein kinase pathway and participant in the formation of PAs. Except PAs, *KIAA1549--BRAF* fusion gene can only be detected in diffuse leptomeningeal glioneuronal tumors.^\[[@R4],[@R9]\]^ Therefore, harboring *KIAA1549--BRAF* fusion gene contributes to the diagnosis of PAs. In our case, the detection of *BRAF* fusion gene was the determining factor in the distinguishing between PA and DNT. In addition to *KIAA1549--BRAF*, other *BRAF* fusion partners were also found in PAs, including *FAM131B*, *RNF130*, *CLCN6*, *MKRN1*, *GNAII,* and *GIT2*.^\[[@R10]\]^ Besides, activating point mutation *BRAF V600E* occurs in a small part of PAs, especially in the supratentorial locations,^\[[@R11]\]^ whereas it is the most common finding in papillary craniopharyngiomas, PXA, gangliogliomas (GG) and DNT.^\[[@R11]\]^ Moreover, aberrant DNA methylation has been studied in PAs, which varied according to tumor locations as well.^\[[@R6]\]^

From a differential diagnosis perspective, our case should be distinguished from DNT. It is well known that DNT is a type of epilepsy-associated low-grade glioneuronal tumor which typically occurs in the cerebral cortex of children and adolescents. After surgery, the recurrence and progression of DNTs are exceptional. Their histological features are multinodular with glioneuronal elements, which contain oligodendrocyte-like cells attached to bundles of axons and neurons with normal cytology floating in a myxoid interstitial fluid.^\[[@R12],[@R13]\]^ In rare cases, DNTs in the septum pellucidum or the supratentorial midline may be misdiagnosed as glioma,^\[[@R14],[@R15]\]^ while astrocytoma with microcystic change and oligodendrocyte-like cells is hard to distinguish from DNT.^\[[@R16]\]^ In our case, both histological morphology and immunophenotype are similar to DNT, molecular detection was the only way to distinguish between PA and DNT. 30% of DNTs harbor *BRAF V600E* mutation,^\[[@R17]\]^ while *KIAA1549--BRAF* fusion gene has never been detected in DNT. Therefore, the detection of *BRAF* fusion gene supports the diagnosis of PA. However, it is important to note that DNT can coexist with PA,^\[[@R18]\]^ and the recurrent DNT may display the morphology of PA.^\[[@R19]\]^ Besides, our case also needs to differentiate from other histologic mimics, including GG, oligodendroglioma and extraventricular neurocytoma. GG is another type of epilepsy-associated low-grade glioneuronal tumor which contains NeuN positive neuronal and GFAP positive glial cell elements. But loose microcystic regions were not easy to see in GG. *BRAF V600E* mutation occurred in 35% GG.^\[[@R20]\]^ However, there has no *BRAF* fusion been detected in GG. It is not uncommon to see oligodendrocyte-like cells in PAs, resulting in some overlapping features with oligodendroglioma or extraventricular neurocytoma. However, oligodendroglioma frequently demonstrates *IDH* mutation and 1p/19q codeletion,^\[[@R4]\]^ while extraventricular neurocytoma diffuse expresses neuronal marker.^\[[@R21]\]^ Both of them have no *BRAF* fusion.

As a WHO grade I glioma, PAs generally have favorable prognosis. The 10-year survival rate is over 95% after operation.^\[[@R3]\]^ Spontaneous regression may be encountered in PAs, especially in patients with neurofibromatosis type 1.^\[[@R3],[@R21]\]^ A small minority of PAs may recur after surgery or disseminate to the leptomeninnges.^\[[@R1],[@R2]\]^ Surgical resection is the first treatment choice for patients with PAs, and radiotherapy or chemotherapy is applied to patients who are inoperable, subtotally resected, or progressive.^\[[@R5]\]^ Eleven months after the operation, our case showed no local recurrence and dissemination.

PAs are heterogeneous tumors in histological morphology, immunophenotype and molecular characteristics. We report here a case of PA that both histological morphology and immunophenotype are similar to DNT, which expanded the morphological profile of PA. Therefore, we suggest that *KIAA1549--BRAF* fusion gene status should be assessed under similar situation to confirm the diagnosis.
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